Literature DB >> 3279976

Active and inactive forms of hemolysin (HlyA) from Escherichia coli.

W Wagner1, M Kuhn, W Goebel.   

Abstract

The HlyA protein (Mr 110 kDa) which is the gene product of the hlyA gene encoded by the hemolysin determinant of Escherichia coli (Goebel, W. & Hedgpeth, J. (1982) J. Bacteriol. 151, 1290-1298) was observed to accumulate in the culture supernatant (in the presence of the three other Hly proteins HlyC, B and D) throughout the active growth cycle. However, the amount of extracellular HlyA protein did not correlate with the external hemolytic activity, which declined when the cells entered the stationary phase. External hemolytic activity was highly sensitive to phospholipase C and to ultrasonication. The size of the HlyA protein on SDS-PAGE was not changed by these treatments although the hemolytic activity was entirely abolished. On a polyacrylamide gel containing 2M urea but only 0.1% SDS hemolytically active HlyA migrated slightly ahead of the inactive HlyA suggesting that HlyA is more negatively charged than HlyA. Active hemolysin from unconcentrated hemolytic supernatants migrated on Sephacryl S-400 and on glycerol gradients as large complexes. Analysis of the hemolytically active fractions on SDS-PAGE yielded in both cases only HlyA (110 kDA) as major protein. An internal hemolytic activity appeared in most Escherichia coli K-12 strains in the stationary phase which was independent of the presence of HlyA or any other Hly gene product. This hemolytic activity which reached in some strains about 10% of the level determined by the hly genes was sensitive to proteinase K and disappeared upon shift of the cells to the logarithmic phase.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279976     DOI: 10.1515/bchm3.1988.369.1.39

Source DB:  PubMed          Journal:  Biol Chem Hoppe Seyler        ISSN: 0177-3593


  16 in total

1.  Separable domains define target cell specificities of an RTX hemolysin from Actinobacillus pleuropneumoniae.

Authors:  D R McWhinney; Y F Chang; R Young; D K Struck
Journal:  J Bacteriol       Date:  1992-01       Impact factor: 3.490

2.  Characterization of monoclonal antibodies against alpha-hemolysin of Escherichia coli.

Authors:  R L Oropeza-Wekerle; P Kern; D Sun; S Muller; J P Briand; W Goebel
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

Review 3.  The different hemolysins of Escherichia coli.

Authors:  L Beutin
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

4.  Domains of Escherichia coli hemolysin (HlyA) involved in binding of calcium and erythrocyte membranes.

Authors:  D F Boehm; R A Welch; I S Snyder
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

5.  Generation of targeted nonpolar gene insertions and operon fusions in Pasteurella haemolytica and creation of a strain that produces and secretes inactive leukotoxin.

Authors:  N D Fedorova; S K Highlander
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

6.  Pore formation by the Escherichia coli hemolysin: evidence for an association-dissociation equilibrium of the pore-forming aggregates.

Authors:  R Benz; A Schmid; W Wagner; W Goebel
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

Review 7.  Bacterial hemolysins as virulence factors.

Authors:  W Goebel; T Chakraborty; J Kreft
Journal:  Antonie Van Leeuwenhoek       Date:  1988       Impact factor: 2.271

8.  Characterization of a sequence (hlyR) which enhances synthesis and secretion of hemolysin in Escherichia coli.

Authors:  M Vogel; J Hess; I Then; A Juarez; W Goebel
Journal:  Mol Gen Genet       Date:  1988-04

9.  The repeat domain of Escherichia coli haemolysin (HlyA) is responsible for its Ca2+-dependent binding to erythrocytes.

Authors:  A Ludwig; T Jarchau; R Benz; W Goebel
Journal:  Mol Gen Genet       Date:  1988-11

10.  Superoxide generation by human neutrophils induced by low doses of Escherichia coli hemolysin.

Authors:  S Bhakdi; E Martin
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.